Overview of Metabolic Dysfunction-Associated Steatohepatitis in Children.
作者信息
Kohli Rohit
机构信息
Chief, Division of Gastroenterology, Hepatology and Nutrition Associate Director, The Saban Research Institute, Children's Hospital Los Angeles Professor of Pediatrics, Keck School of Medicine of USC Los Angeles, California.
出版信息
Gastroenterol Hepatol (N Y). 2025 Apr;21(4):255-258.
Abstract
摘要
相似文献
1
Overview of Metabolic Dysfunction-Associated Steatohepatitis in Children.儿童代谢功能障碍相关脂肪性肝炎概述
Gastroenterol Hepatol (N Y). 2025 Apr;21(4):255-258.
2
Pharmacological SERCA activation limits diet-induced steatohepatitis and restores liver metabolic function in mice.药物性 SERCA 激活可限制饮食诱导的脂肪性肝炎，并恢复小鼠的肝脏代谢功能。
J Lipid Res. 2024 Jun;65(6):100558. doi: 10.1016/j.jlr.2024.100558. Epub 2024 May 8.
3
Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.基于性别的差异，自然杀伤 T 细胞在保护 Balb/c 小鼠抵抗饮食诱导的脂肪性肝炎中的作用。
Biol Sex Differ. 2023 Nov 14;14(1):85. doi: 10.1186/s13293-023-00569-w.
4
Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems.部署与代谢功能障碍相关的脂肪性肝炎共识护理路径：三项卫生系统教育试点的结果。
BMC Prim Care. 2024 Jul 20;25(1):265. doi: 10.1186/s12875-024-02517-y.
5
Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.代谢功能障碍相关脂肪性肝病相关肝肿瘤的病理学与发病机制
Biomedicines. 2023 Oct 12;11(10):2761. doi: 10.3390/biomedicines11102761.
6
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.代谢功能障碍相关脂肪性肝病增加慢性乙型肝炎患者不良结局的风险。
JHEP Rep. 2021 Aug 8;3(5):100350. doi: 10.1016/j.jhepr.2021.100350. eCollection 2021 Oct.
7
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.代谢功能障碍相关脂肪性肝病（MASLD）和代谢功能障碍相关脂肪性肝炎（MASH）对心脏、肌肉和肾脏相关疾病的全身影响。
Front Cell Dev Biol. 2024 Jul 16;12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024.
8
Treatment of rapid recurrence of severe steatosis with combined glucagon-like peptide-1 agonist and growth hormone therapy in a pediatric patient transplanted for metabolic dysfunction-associated steatohepatitis cirrhosis in the setting of hypopituitarism.在一名因代谢功能障碍相关脂肪性肝炎肝硬化合并垂体功能减退而接受移植的儿科患者中，联合使用胰高血糖素样肽-1激动剂和生长激素疗法治疗严重脂肪变性的快速复发。
Am J Transplant. 2025 May;25(5):1123-1126. doi: 10.1016/j.ajt.2025.01.002. Epub 2025 Jan 8.
9
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.代谢功能障碍相关脂肪性肝炎的当前治疗现状
Int J Mol Sci. 2025 Feb 19;26(4):1778. doi: 10.3390/ijms26041778.
10
Prognostic Relevance of Metabolic Dysfunction-associated Steatohepatitis for Patients with Chronic Hepatitis B.代谢功能障碍相关脂肪性肝炎对慢性乙型肝炎患者的预后相关性
J Clin Transl Hepatol. 2023 Feb 28;11(1):76-87. doi: 10.14218/JCTH.2022.00055. Epub 2022 May 23.
本文引用的文献
1
Dihydroxyacetone phosphate is a novel predictor of hepatic fibrosis in Latino adolescents with obesity.磷酸二羟丙酮是肥胖拉丁裔青少年肝纤维化的一种新型预测指标。
J Pediatr Gastroenterol Nutr. 2025 Jan;80(1):174-181. doi: 10.1002/jpn3.12420. Epub 2024 Nov 25.
2
Approach to the Treatment of Children and Adolescents with Obesity.肥胖儿童和青少年的治疗方法。
Gastrointest Endosc Clin N Am. 2024 Oct;34(4):781-804. doi: 10.1016/j.giec.2024.06.004. Epub 2024 Aug 14.
3
Effect of N-acetyl cysteine in children with metabolic dysfunction-associated steatotic liver disease-A pilot study.N-乙酰半胱氨酸对代谢功能障碍相关脂肪性肝病患儿的疗效：一项初步研究。
J Pediatr Gastroenterol Nutr. 2024 Sep;79(3):652-660. doi: 10.1002/jpn3.12312. Epub 2024 Jul 8.
4
Pediatric NASH therapies: A speedbump on the road to success.儿童非酒精性脂肪性肝炎疗法：通往成功之路上的一个障碍。
Hepatology. 2022 Aug;76(2):292-294. doi: 10.1002/hep.32322. Epub 2022 Feb 22.
5
Incidence of Nonalcoholic Fatty Liver Disease in Children: 2009-2018.儿童非酒精性脂肪性肝病的发病率：2009-2018 年。
Pediatrics. 2020 Dec;146(6). doi: 10.1542/peds.2020-0771.
6
NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).NASPGHAN儿童非酒精性脂肪性肝病诊断与治疗临床实践指南：非酒精性脂肪性肝病专家委员会（ECON）及北美儿科胃肠病学、肝病学和营养学会（NASPGHAN）的建议
J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):319-334. doi: 10.1097/MPG.0000000000001482.
7
A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD.多学科临床方案可有效稳定 BMI 并降低 NAFLD 患儿的转氨酶水平。
J Pediatr Gastroenterol Nutr. 2013 Jul;57(1):119-23. doi: 10.1097/MPG.0b013e318290d138.
8
Histopathology of pediatric nonalcoholic fatty liver disease.小儿非酒精性脂肪性肝病的组织病理学
Hepatology. 2005 Sep;42(3):641-9. doi: 10.1002/hep.20842.
Zotero 插件